Infervision, a Chinese artificial intelligence (AI) start-up specialized in medical imaging technology, has completed a series C1 round of financing led by China’s alternative asset management firm CDH Investments, with China Taihecap continues to serve as the exclusive financial advisor.

The new funding round, without disclosing the financial details, also saw the participation of Sequoia Capital, private equity firm Haitong Capital, growth-stage internet firms-focused Genesis Capital and Taihe Capital, and technology, media and telecom-focused Xianghe Capital. Taihe Capital serves as the exclusive financial adviser of the deal.

Infervision, ranked among China Money Network’s China AI Top 50, was founded in January 2015 and is headquartered in Beijing. The company applies deep learning technology to medical image analysis.

Utilizing massive medical data, Infervision creates clinically-valuable products and facilitates radiologists to make faster and more accurate diagnoses. The company has formed partnerships with 200 hospitals, according to a statement released by Infervision in early September.

Source: https://www.chinamoneynetwork.com/2018/12/10/cdh-investments-leads-series-c1-round-in-ai-powered-medical-imaging-firm-infervision